Apellis Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio5.0817.8975.8169.1517.28
P/B Ratio17.3736.4733.6623.1721.18
Price/Tangible Book17.3736.4733.6623.1721.18
Enterprise Value Ratios
EV/Revenue5.1716.9967.9265.8715.87
Profitability & Returns
Return on Equity (ROE)-0.94%-2.90%-3.54%-3.70%-2.89%
Return on Assets (ROA)-0.12%-0.42%-0.45%-0.36%-0.20%
Return on Capital Employed (ROCE)-0.24%-0.96%-1.00%-0.71%-0.26%
Leverage & Solvency Ratios
Debt/Equity2.060.570.661.061.85
Liquidity Ratios
Current Ratio4.253.104.296.257.15
Quick Ratio3.712.343.565.937.03
Efficiency Ratios
Asset Turnover0.930.510.090.070.37
Inventory Turnover3.633.156.35
Yield & Distribution Ratios
Earnings Yield-0.05%-0.07%-0.11%-0.16%-0.08%
FCF Yield-0.02%-0.08%-0.09%-0.12%-0.04%
Buyback Yield-0.04%-0.12%-0.26%-0.12%-0.21%